Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2013 Jun;60(6):985-93. doi: 10.1002/pbc.24433. Epub 2012 Dec 19.

Children's Oncology Group's 2013 blueprint for research: neuroblastoma.

Author information

1
Seattle Children's Hospital, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA 98106, USA. julie.park@seattlechildrens.org

Erratum in

  • Pediatr Blood Cancer. 2014 May;61(5):958. Mattay, Katherine M [corrected to Mattay, Katherine K].

Abstract

Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors.

PMID:
23255319
DOI:
10.1002/pbc.24433
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center